Please assess the completion status of the following clinical trial:

Trial Title: Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with all types of non-valvular AF (includes paroxysmal, persistent and permanent AF)~2. Candidate for anticoagulation therapy~3. No contra-indication for LGE-MRI~4. Patients age 18 and older~5. Patients who are able to provide informed consent to participate in the study~Exclusion Criteria:~1. Patients who have already undergone an atrial fibrillation ablation procedure.~2. Patients with active contra-indications to any anticoagulant agent.~3. Other major bleeding disorders or risk factors that would place the patient at risk of bleeding.~4. Recent surgery (within 30 days).~5. Renal insufficiency, severe kidney disorders/diseases, GFR \< 30mg/dL (Gadolinium contraindication).~6. Advanced liver disease.~7. Any health related Gadolinium/MRI contraindications: Pacemaker devices, etc.~8. Pregnant, planning to be become pregnant or nursing women~9. Individuals who are unable to provide informed consent~10. Contraindicated for Pradaxa® .~11. Patients the Investigators feel are inappropriate for the study~12. Patients who cannot give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabigatran (Type: EXPERIMENTAL): Patients with Atrial fibrillation taking Dabigatran etexilate as the anti-coagulant

Based on this trial design, predict the completion outcome and termination type (if applicable).